Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Dalfampridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,496Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
    Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

    11 Jul 2024

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/merz-wins-185m-bid-for-bankrupt-acorda-assets-and-increases-us-workforce-by-50/

    PHARMACEUTICAL-TECHNOLOGY
    11 Jul 2024
    Share Share
    Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
    Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

    10 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240710459851/en

    BUSINESSWIRE
    10 Jul 2024
    Share Share
    Acorda files for bankruptcy, inks $185M asset deal to Merz
    Acorda files for bankruptcy, inks $185M asset deal to Merz

    03 Apr 2024

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/acorda-inks-185m-asset-deal-merz-therapeutics-files-bankruptcy-after-years-disappointing

    Zoey Becker FIERCE PHARMA
    03 Apr 2024
    Share Share
    Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
    Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401939079/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
    Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda

    12 Jan 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biogen-returns-ex-us-rights-ms-drug-fampyra-acorda

    Kevin Dunleavy FIERCE PHARMA
    12 Jan 2024
    Share Share
    NICE opts to reject Acorda’s MS drug Fampyra
    NICE opts to reject Acorda’s MS drug Fampyra

    22 Jun 2022

    // John Pinching PHARMATIMES

    https://www.pharmatimes.com/news/nice_opts_to_reject_acordas_ms_drug_fampyra_1450334

    John Pinching PHARMATIMES
    22 Jun 2022
    Share Share